Stocks Hitting 52-Week Lows

shares fell 30.66 percent to touch a new 52-week low of $28.23 following announced delay to 10-K filing, cancelled buyback and delayed investor day.

shares touched a new 52-week low of $3.89. Celldex Therapeutics will discontinue its Phase 3 study of RINTEGA for newly diagnosed glioblastoma.

shares fell 0.69 percent to reach a new 52-week low of $4.30. SCYNEXIS reported a FY15 loss of $2.68 per share.

shares fell 3.49 percent to touch a new 52-week low of $15.78. Heritage Insurance shares have tumbled 26.88 percent over the past 52 weeks, while the S&P 500 index has dropped 3.82 percent in the same period.